Probability of discontinuation of all immunosuppressive agents after nonmyeloablative or myeloablative conditioning. Death and rejection during immunosuppressive therapy are shown as competing risks. The area between the curves represents patients continuing with immunosuppressive therapy for GVHD. Four patients who underwent nonmyeloablative HSCT and one who underwent myeloablative HSCT discontinued the use of all immunosuppressive agents during the follow-up period. The difference was not significant (P = .25; log-rank test). IS indicates immunosuppression.